150 completed, 19 terminated, 8 recruiting, 6 active not recruiting. 67 Phase 2, 65 Phase 1, 55 Phase 3, 7 Phase 4.
Follow Kyowa Kirin Co., Ltd.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of KK2430 in Participants With Hematologic Neoplasms KK2430 - Hematologic Neoplasms | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 72 | 2026-08-01 | 2026-08-07 |
| A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia ziftomenib - Acute Myeloid Leukemia (AML) | Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 6 | 2026-04-23 | 2026-06-03 |
| Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result Surveillance Poteligeo 20mg - Mycosis Fungoides, Sezary Syndrome | Recruiting | Kyowa Kirin Co., Ltd. | 15 | 2025-05-02 | 2025-09-22 | |
| Study of KK3910 in Healthy Volunteers and Patients With Essential Hypertension Placebo, KK3910 - Healthy Volunteers Essential Hypertension | Phase 1 | Recruiting | Kyowa Kirin Co., Ltd. | 160 | 2025-04-03 | 2026-07-01 |
| Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study） KK8398 - Achondroplasia | Phase 3 | Active not recruiting | Kyowa Kirin Co., Ltd. | 13 | 2024-12-01 | 2026-10-08 |
| Phase I Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Other Hematologic Malignancies. KK2845_1, KK2845_2, KK2845_3 - Relapsed or Refractory AML and Other Hematologic Malignancies | Phase 1 | Recruiting | Kyowa Kirin Co., Ltd. | 156 | 2024-10-10 | 2026-07-01 |
| A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia KK8123 - X-linked Hypophosphatemia | Phase 1 / Phase 2 | Recruiting | Kyowa Kirin Co., Ltd. | 39 | 2024-10-09 | 2026-09-21 |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration KHK4951, Aflibercept Injection - Neovascular Age-Related Macular Degeneration (nAMD) | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 170 | 2024-01-31 | 2026-10-14 |
| A Study of KK2269 in Adult Participants With Solid Tumors KK2269, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Recruiting | Kyowa Kirin Co., Ltd. | 101 | 2024-01-18 | 2026-09-10 |
| Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema KHK4951, Aflibercept Injection - Diabetic Macular Edema (DME) | Phase 2 | Active not recruiting | Kyowa Kirin Co., Ltd. | 185 | 2024-01-09 | 2026-10-14 |
| A Clinical Study of KK2260 in Patients With Advanced or Metastatic Solid Tumors KK2260 - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Kyowa Kirin Co., Ltd. | 189 | 2023-11-01 | 2026-05-27 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With TIO KRN23 - Tumor-Induced Osteomalacia (TIO) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 9 | 2022-09-07 | 2024-07-09 |
| A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus Placebo, KK4277 - Healthy Volunteers, Systemic Lupus Erythematosus (SLE) | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 125 | 2022-08-03 | 2026-09-29 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Pediatric Chinese Patients With XLH KRN23 - X-linked Hypophosphatemia (XLH) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 28 | 2021-11-01 | 2024-07-09 |
| Study to Assess the Safety, Pharmacokinetics and Efficacy of KRN23 in Adult Chinese Patients With XLH KRN23 - X-linked Hypophosphatemia (XLH) | Phase 4 | Completed | Kyowa Kirin Co., Ltd. | 18 | 2021-09-28 | 2024-07-09 |
| A Study of KRN125 in Patients With Multiple Myeloma and Malignant Lymphoma KRN125(pegfilgrastim), PLR001(plerixafor), KRN8601(filgrastim), PLR001(plerixafor) - Multiple Myeloma and Malignant Lymphoma | Phase 2 | Completed | Kyowa Kirin Co., Ltd. | 64 | 2021-09-01 | 2023-02-21 |
| Long Term Follow-up Observational Study After Clinical Trials of AMG531 (Romiplostim) in Patients With Untreated Aplastic Anemia Aplastic Anemia | Active not recruiting | Kyowa Kirin Co., Ltd. | 36 | 2021-05-10 | 2025-09-11 | |
| Phosphate Binder Switch Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791 - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 213 | 2021-03-15 | 2023-08-02 |
| Phosphate Binder-combination Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791, Placebo - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 169 | 2021-03-15 | 2021-10-28 |
| Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis KHK7791, Placebo - Hyperphosphatemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 165 | 2021-03-08 | 2021-09-08 |
Showing 20 of 186. Sign in to see all of them.
Parkinson Disease (22) · Familial Hypophosphatemic Rickets (16) · Diabetes Mellitus, Type 2 (9) · Neoplasms (8) · Hyperparathyroidism, Secondary (7) · Hyperphosphatemia (7) · Psoriasis (7) · Carcinoma, Non-Small-Cell Lung (5) · Anemia, Aplastic (4) · Breast Neoplasms (4) · Dermatitis, Atopic (4) · Lymphoma, T-Cell, Peripheral (4) · Multiple Myeloma (4) · Alzheimer Disease (3) · Cancer Pain (3)
burosumab (16) · istradefylline (14) · brodalumab (11) · mogamulizumab (11) · ARQ 197 (8) · Granisetron (5) · bleselumab (5) · romiplostim (5) · Cinacalcet (4) · Fentanyl (4) · Darbepoetin alfa (3) · Erlotinib Hydrochloride (3) · KHK4083 (3) · Sodium Chloride (3) · bardoxolone methyl (3)
Japan (123) · United States (44) · South Korea (18) · Canada (12) · United Kingdom (11) · France (7) · China (6) · Germany (6) · Australia (5) · Italy (5) · Netherlands (4) · Poland (3) · Serbia (3) · Sweden (3) · Taiwan (3)
Michael Kurman, MD (5) · Amy Zhang, PhD (3) · Stuart J Mair (3) · Marc Cantillon, M.D. (2) · Nagahiro Saijo, MD (2) · Neil Sussman, MD (2) · Sotaro Takigawa (2) · Amy Zhang, PhD. (1) · Beverley Hunt, FRCP, FRCPath MD (1) · Bridget O'Mahony, PhD (1)
PMID 39151033, PMID 42664364, PMID 25919461, PMID 32721016, PMID 36719566, PMID 40498549, PMID 40962182, PMID 19814586, PMID 20075341, PMID 20835873, PMID 21030700, PMID 21208151, PMID 21426510, PMID 22312108, PMID 23100308, PMID 23753021, PMID 24569459, PMID 24616310, PMID 24752449, PMID 24839047, PMID 25378647, PMID 25605368, PMID 25733162, PMID 25874620, PMID 25922903, PMID 26073451, PMID 26153496, PMID 26507836, PMID 26547109, PMID 27418646, PMID 27457707, PMID 27843623, PMID 28261656, PMID 29791829, PMID 29947083, PMID 30473794, PMID 30955188, PMID 31104833, PMID 31165191, PMID 31397943, PMID 31455681, PMID 31509331, PMID 31801624, PMID 32601114, PMID 32716114, PMID 33045994, PMID 33484279, PMID 33827787, PMID 34548383, PMID 34636899
2009 (2), 2014 (1)